Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

CAMBRIDGE, Mass.–()–Syros
(NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of genes, today announced that the Company will present on
the design of its Phase 1 clinical trial of SY-1365, a first-in-class
selective cyclin-dependent kinase 7 (CDK7) inhibitor, at the American
Society of Clinical Oncology (ASCO) Annual Meeting taking place June
1-5, 2018 in Chicago.

The Phase 1 trial is currently enrolling advanced solid tumor patients
in the dose-escalation portion of the trial, with planned expansion
cohorts to further evaluate SY-1365 as a single agent and in combination
with standard-of-care therapies in multiple ovarian and breast cancer
patient populations. Syros expects to open the expansion phase of the
trial in mid-2018 and to report data from the dose-escalation portion of
the trial in the fourth quarter of 2018.

Details on the presentations are as follows:

Date & Time: Monday, June 4, 8:00 a.m. – 11:30 a.m. CDT
Title: Trial Design of a First-in-Human Phase 1 Evaluation of SY-1365, a
Class Selective CDK7 Inhibitor, with Initial Expansions
in Ovarian and Breast Cancers
Session Title: Developmental
Therapeutics—Clinical Pharmacology and Experimental
Geoffrey Shapiro, M.D., Ph.D., Dana-Farber Cancer Institute
Number: TPS2600
Location: McCormick Place, Hall A

About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding region of the genome to advance a new
wave of medicines that control expression of genes. Syros has built a
proprietary platform that is designed to systematically and efficiently
analyze this unexploited region of DNA in human disease tissue to
identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of
all cells, Syros’ gene control platform has broad potential to create
medicines that achieve profound and durable benefit across a range of
diseases. Syros is currently focused on cancer and monogenic diseases
and is advancing a growing pipeline of gene control medicines. Syros’
lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2
clinical trial for genomically defined subsets of patients with acute
myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective
CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced
solid tumors. Led by a team with deep experience in drug discovery,
development and commercialization, Syros is located in Cambridge, Mass.

Cautionary Note Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the Company’s ability to open the
expansion phase of the Phase 1 clinical trial of SY-1365 in ovarian and
breast cancer in mid-2018 and to report data from the dose escalation
portion of the trial in the fourth quarter of 2018, and the benefits of
Syros’ gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’
‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’
‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including Syros’ ability to: advance the development of its
programs, including SY-1365, under the timelines it projects in current
and future clinical trials; demonstrate in any current and future
clinical trials the requisite safety, efficacy and combinability of its
drug candidates; replicate scientific and non-clinical data in clinical
trials; successfully develop a companion diagnostic test to identify
patients with predictive biomarkers; obtain and maintain patent
protection for its drug candidates and the freedom to operate under
third party intellectual property; obtain and maintain necessary
regulatory approvals; identify, enter into and maintain collaboration
agreements with third parties, including its ability to perform under
the collaboration agreement with Incyte; manage competition; manage
expenses; raise the substantial additional capital needed to achieve its
business objectives; attract and retain qualified personnel; and
successfully execute on its business strategies; risks described under
the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the
year ended December 31, 2017, as updated in its Quarterly Report on Form
10-Q for the quarter ended March 31, 2018, each of which is on file with
the Securities and Exchange Commission; and risks described in other
filings that Syros makes with the Securities and Exchange Commission in
the future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Syros expressly disclaims
any obligation to update any forward-looking statements, whether because
of new information, future events or otherwise.

Source link

Leave a Reply

Your email address will not be published.